

Yong Song

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1064716/publications.pdf>

Version: 2024-02-01

212
papers

7,542
citations

57758

44
h-index

74163

75
g-index

216
all docs

216
docs citations

216
times ranked

11949
citing authors

#	ARTICLE	IF	CITATIONS
1	Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. <i>Lancet Oncology</i> , The, 2013, 14, 953-961.	10.7	389
2	Encephalitis as a clinical manifestation of COVID-19. <i>Brain, Behavior, and Immunity</i> , 2020, 88, 945-946.	4.1	345
3	Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. <i>Journal of Medical Virology</i> , 2020, 92, 1890-1901.	5.0	334
4	A critical role for the long non-coding RNA GAS5 in proliferation and apoptosis in non-small cell lung cancer. <i>Molecular Carcinogenesis</i> , 2015, 54, E1-E12.	2.7	261
5	Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology) <i>TJ ETQq1 1 0.17843142381 / Over</i>	10.7	166
6	Prolonged SARS-CoV-2 RNA shedding: Not a rare phenomenon. <i>Journal of Medical Virology</i> , 2020, 92, 2286-2287.	5.0	177
7	Downregulation of GSDMD attenuates tumor proliferation via the intrinsic mitochondrial apoptotic pathway and inhibition of EGFR/Akt signaling and predicts a good prognosis in non-small cell lung cancer. <i>Oncology Reports</i> , 2018, 40, 1971-1984.	2.6	169
8	Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial. <i>Lancet Respiratory Medicine</i> , the, 2018, 6, 681-690.	10.7	166
9	The growth arrest-specific transcript 5 (GAS5): a pivotal tumor suppressor long noncoding RNA in human cancers. <i>Tumor Biology</i> , 2016, 37, 1437-1444.	1.8	159
10	Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients. <i>Journal of Translational Medicine</i> , 2019, 17, 355.	4.4	150
11	The long non-coding RNA HNF1A-AS1 regulates proliferation and metastasis in lung adenocarcinoma. <i>Oncotarget</i> , 2015, 6, 9160-9172.	1.8	141
12	The role of TWIST1 in epithelial-mesenchymal transition and cancers. <i>Tumor Biology</i> , 2016, 37, 185-197.	1.8	133
13	Tumor-derived exosomal lncRNA GAS5 as a biomarker for early-stage non-small cell lung cancer diagnosis. <i>Journal of Cellular Physiology</i> , 2019, 234, 20721-20727.	4.1	118
14	GSDMD is required for effector CD8+ T cell responses to lung cancer cells. <i>International Immunopharmacology</i> , 2019, 74, 105713.	3.8	114
15	Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 45-53.	10.7	105
16	Downregulation of the long noncoding RNA GAS5-AS1 contributes to tumor metastasis in non-small cell lung cancer. <i>Scientific Reports</i> , 2016, 6, 31093.	3.3	102
17	Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. <i>Cancer Cell</i> , 2021, 39, 1279-1291.e3.	16.8	99
18	Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis. <i>Translational Lung Cancer Research</i> , 2017, 6, S8-S20.	2.8	97

#	ARTICLE	IF	CITATIONS
19	The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials. <i>Translational Lung Cancer Research</i> , 2019, 8, 413-428.	2.8	95
20	Concomitant neurological symptoms observed in a patient diagnosed with coronavirus disease 2019. <i>Journal of Medical Virology</i> , 2020, 92, 1782-1784.	5.0	93
21	Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment. <i>Translational Lung Cancer Research</i> , 2019, 8, 302-316.	2.8	91
22	Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patients. <i>Thoracic Cancer</i> , 2015, 6, 275-287.	1.9	88
23	PRC1 contributes to tumorigenesis of lung adenocarcinoma in association with the Wnt/ β -catenin signaling pathway. <i>Molecular Cancer</i> , 2017, 16, 108.	19.2	81
24	Expression profiles and clinical value of plasma exosomal Tim-3 and Galectin-9 in non-small cell lung cancer. <i>Biochemical and Biophysical Research Communications</i> , 2018, 498, 409-415.	2.1	81
25	The biology, function and clinical implications of exosomes in lung cancer. <i>Cancer Letters</i> , 2017, 407, 84-92.	7.2	78
26	Diagnostic Accuracy of CT-Guided Transthoracic Needle Biopsy for Solitary Pulmonary Nodules. <i>PLoS ONE</i> , 2015, 10, e0131373.	2.5	76
27	Intratracheal administration of mitochondrial DNA directly provokes lung inflammation through the TLR9-p38 MAPK pathway. <i>Free Radical Biology and Medicine</i> , 2015, 83, 149-158.	2.9	76
28	Two plasma microRNA panels for diagnosis and subtype discrimination of lung cancer. <i>Lung Cancer</i> , 2018, 123, 44-51.	2.0	75
29	Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2109-2120.	1.1	75
30	PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer. <i>Cancer Letters</i> , 2015, 359, 218-225.	7.2	73
31	Pretreatment platelet-to-lymphocyte ratio (PLR) as a predictor of response to first-line platinum-based chemotherapy and prognosis for patients with non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2013, 5, 783-9.	1.4	73
32	NatD promotes lung cancer progression by preventing histone H4 serine phosphorylation to activate Slug expression. <i>Nature Communications</i> , 2017, 8, 928.	12.8	69
33	Extracellular mitochondrial DNA promote NLRP3 inflammasome activation and induce acute lung injury through TLR9 and NF- κ B. <i>Journal of Thoracic Disease</i> , 2019, 11, 4816-4828.	1.4	67
34	Upregulation of long intergenic noncoding RNA 00673 promotes tumor proliferation via LSD1 interaction and repression of NCALD in non-small-cell lung cancer. <i>Oncotarget</i> , 2016, 7, 25558-25575.	1.8	66
35	Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis. <i>Translational Lung Cancer Research</i> , 2019, 8, 214-226.	2.8	66
36	Pulmonary ground-glass opacity: computed tomography features, histopathology and molecular pathology. <i>Translational Lung Cancer Research</i> , 2017, 6, 68-75.	2.8	64

#	ARTICLE	IF	CITATIONS
37	Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort. <i>Translational Lung Cancer Research</i> , 2020, 9, 269-279.	2.8	64
38	A Serum Vitamin D Level $\leq 25\text{nmol/L}$ Pose High Tuberculosis Risk: A Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0126014.	2.5	61
39	Long non-coding RNA 00312 regulated by HOXA5 inhibits tumour proliferation and promotes apoptosis in Non-small cell lung cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 2184-2198.	3.6	59
40	Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer. <i>Cancer Letters</i> , 2021, 500, 163-171.	7.2	55
41	The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients. <i>Translational Lung Cancer Research</i> , 2019, 8, 429-449.	2.8	54
42	Long intergenic noncoding RNA 00673 promotes non-small-cell lung cancer metastasis by binding with EZH2 and causing epigenetic silencing of HOXA5. <i>Oncotarget</i> , 2017, 8, 32696-32705.	1.8	51
43	Comparison between endobronchial ultrasound-guided transbronchial biopsy and CT-guided transthoracic lung biopsy for the diagnosis of peripheral lung cancer: a systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2017, 6, 23-34.	2.8	50
44	TLR4 mediates LPS-induced HO-1 expression in mouse liver: Role of TNF- α and IL-1 β . <i>World Journal of Gastroenterology</i> , 2003, 9, 1799.	3.3	48
45	Crocin inhibits cell proliferation and enhances cisplatin and pemetrexed chemosensitivity in lung cancer cells. <i>Translational Lung Cancer Research</i> , 2015, 4, 775-83.	2.8	48
46	sRAGE alleviates neutrophilic asthma by blocking HMGB1/RAGE signalling in airway dendritic cells. <i>Scientific Reports</i> , 2017, 7, 14268.	3.3	45
47	LncRNA GMDS-AS1 inhibits lung adenocarcinoma development by regulating miR-96/CYLD signaling. <i>Cancer Medicine</i> , 2020, 9, 1196-1208.	2.8	45
48	PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis. <i>Translational Lung Cancer Research</i> , 2015, 4, 203-8.	2.8	43
49	NCAPG2 promotes tumour proliferation by regulating G2/M phase and associates with poor prognosis in lung adenocarcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 665-676.	3.6	41
50	Anti-HMGB1 Neutralizing Antibody Ameliorates Neutrophilic Airway Inflammation by Suppressing Dendritic Cell-Mediated Th17 Polarization. <i>Mediators of Inflammation</i> , 2014, 2014, 1-11.	3.0	39
51	Detection of EML4-ALK in Lung Adenocarcinoma Using Pleural Effusion with FISH, IHC, and RT-PCR Methods. <i>PLoS ONE</i> , 2015, 10, e0117032.	2.5	39
52	Elevated pretreatment serum globulin albumin ratio predicts poor prognosis for advanced non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2014, 6, 1261-70.	1.4	39
53	The overexpression of KIFC1 was associated with the proliferation and prognosis of non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2016, 8, 2911-2923.	1.4	37
54	PiggyBac transposon vectors: the tools of the human gene encoding. <i>Translational Lung Cancer Research</i> , 2016, 5, 120-5.	2.8	36

#	ARTICLE	IF	CITATIONS
55	PaO ₂ /FIO ₂ and IL-6 are risk factors of mortality for intensive care COVID-19 patients. <i>Scientific Reports</i> , 2021, 11, 7334.	3.3	35
56	Identification of novel driver mutations of the discoidin domain receptor 2 (DDR2) gene in squamous cell lung cancer of Chinese patients. <i>BMC Cancer</i> , 2014, 14, 369.	2.6	33
57	Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis. <i>Journal of Thoracic Disease</i> , 2018, 10, 6636-6652.	1.4	33
58	TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib. <i>Journal of Thoracic Disease</i> , 2018, 10, 2991-2998.	1.4	31
59	The effect of P2X7 receptor 1513 polymorphism on susceptibility to tuberculosis: A meta-analysis. <i>Infection, Genetics and Evolution</i> , 2014, 24, 82-91.	2.3	30
60	Recombinant HMGB1 A box protein inhibits Th17 responses in mice with neutrophilic asthma by suppressing dendritic cell-mediated Th17 polarization. <i>International Immunopharmacology</i> , 2015, 24, 110-118.	3.8	30
61	<scp>TEAD</scp>4 exerts proâ€metastatic effects and is negatively regulated by miR6839â€3p in lung adenocarcinoma progression. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 3560-3571.	3.6	30
62	Clinical characteristics, laboratory abnormalities and CT findings of COVID-19 patients and risk factors of severe disease: a systematic review and meta-analysis. <i>Annals of Palliative Medicine</i> , 2021, 10, 1928-1949.	1.2	30
63	Patterns and functional implications of platelets upon tumor â€educationâ€. <i>International Journal of Biochemistry and Cell Biology</i> , 2017, 90, 68-80.	2.8	28
64	A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506). <i>BMC Cancer</i> , 2017, 17, 462.	2.6	28
65	Inhibition of GGPS1 attenuated LPS-induced acute lung injury and was associated with NLRP3 inflammasome suppression. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2019, 316, L567-L577.	2.9	28
66	Elevated exosome-derived miRNAs predict osimertinib resistance in non-small cell lung cancer. <i>Cancer Cell International</i> , 2021, 21, 428.	4.1	28
67	Targeting the ubiquitination/deubiquitination process to regulate immune checkpoint pathways. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 28.	17.1	28
68	Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer. <i>Respiratory Research</i> , 2021, 22, 189.	3.6	27
69	Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 698832.	2.8	27
70	MET-UBE2H Fusion as a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2018, 13, e202-e204.	1.1	26
71	Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 631949.	2.8	26
72	Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1403-1414.	1.1	26

#	ARTICLE	IF	CITATIONS
73	Efficacy and safety of Abraxane in treatment of progressive and recurrent non-small cell lung cancer patients: A retrospective clinical study. Thoracic Cancer, 2012, 3, 341-347.	1.9	25
74	Computed tomography and clinical features associated with epidermal growth factor receptor mutation status in stage I/II lung adenocarcinoma. Thoracic Cancer, 2017, 8, 260-270.	1.9	25
75	Management strategy of solitary pulmonary nodules. Journal of Thoracic Disease, 2013, 5, 824-9.	1.4	25
76	Can EGFR mutations in plasma or serum be predictive markers of non-small-cell lung cancer? A meta-analysis. Lung Cancer, 2015, 88, 246-253.	2.0	24
77	Biomarkers for patients with trauma associated acute respiratory distress syndrome. Military Medical Research, 2017, 4, 25.	3.4	24
78	ALK and ROS1 rearrangements, coexistence and treatment in epidermal growth factor receptor-wild type lung adenocarcinoma: a multicenter study of 732 cases. Journal of Thoracic Disease, 2017, 9, 3919-3926.	1.4	24
79	WNT5B exerts oncogenic effects and is negatively regulated by miR-5587-3p in lung adenocarcinoma progression. Oncogene, 2020, 39, 1484-1497.	5.9	24
80	Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing. Journal of Thoracic Oncology, 2021, 16, 827-839.	1.1	24
81	Metastasis-associated fibroblasts: an emerging target for metastatic cancer. Biomarker Research, 2021, 9, 47.	6.8	24
82	CDCA7 promotes lung adenocarcinoma proliferation via regulating the cell cycle. Pathology Research and Practice, 2019, 215, 152559.	2.3	23
83	Prognostic value of FGFR1 gene copy number in patients with non-small cell lung cancer: a meta-analysis. Journal of Thoracic Disease, 2014, 6, 803-9.	1.4	23
84	Prognostic significance of β -catenin expression in patients with non-small cell lung cancer: a meta-analysis. Translational Lung Cancer Research, 2017, 6, 97-108.	2.8	22
85	Overexpression of geranylgeranyl diphosphate synthase contributes to tumour metastasis and correlates with poor prognosis of lung adenocarcinoma. Journal of Cellular and Molecular Medicine, 2018, 22, 2177-2189.	3.6	22
86	EGFR-RAD51 fusion variant in lung adenocarcinoma and response to erlotinib: A case report. Lung Cancer, 2018, 115, 131-134.	2.0	22
87	Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 432-439.	1.3	21
88	Chinese Expert Recommendation for Diagnosis and Treatment of Massive Hemoptysis. Respiration, 2020, 99, 83-92.	2.6	21
89	Something in need is something indeed. Translational Lung Cancer Research, 2012, 1, 1-2.	2.8	21
90	Prognostic value of the expression of estrogen receptor β in patients with non-small cell lung cancer: a meta-analysis. Translational Lung Cancer Research, 2016, 5, 202-207.	2.8	20

#	ARTICLE	IF	CITATIONS
91	Anti-angiogenic efficacy of 5â€²-triphosphate siRNA combining VEGF silencing and RIG-I activation in NSCLCs. <i>Oncotarget</i> , 2015, 6, 29664-29674.	1.8	20
92	Clinical outcomes of cyberknife stereotactic radiosurgery for lung metastases. <i>Journal of Thoracic Disease</i> , 2015, 7, 407-12.	1.4	20
93	Correlation in histological subtypes with high resolution computed tomography signatures of early stage lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2017, 6, 14-22.	2.8	19
94	Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1857-1870.	1.1	19
95	Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790Mâ€”positive Nonâ€”Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study. <i>Clinical Cancer Research</i> , 2020, 26, 6168-6175.	7.0	19
96	Blocking SphK1/S1P/S1PR1 Signaling Pathway Alleviates Lung Injury Caused by Sepsis in Acute Ethanol Intoxication Mice. <i>Inflammation</i> , 2021, 44, 2170-2179.	3.8	19
97	Diagnostic and therapeutic value of progastrinâ€”releasing peptide on smallâ€”cell lung cancer: A Singleâ€”Center Experience in China. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 4328-4334.	3.6	18
98	Topotecan Alleviates Lipopolysaccharide-Mediated Acute Lung Injury Via the NF-Î²B Signaling Pathway. <i>Journal of Surgical Research</i> , 2019, 235, 83-92.	1.6	18
99	Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study. <i>Translational Lung Cancer Research</i> , 2020, 9, 1853-1861.	2.8	18
100	RNA sequencing enables systematic identification of platelet transcriptomic alterations in NSCLC patients. <i>Biomedicine and Pharmacotherapy</i> , 2018, 105, 204-214.	5.6	17
101	Molecular Characteristics and Clinical Outcomes of EGFR Exon 19 C-Helix Deletion in Nonâ€”Small Cell Lung Cancer and Response to EGFR TKIs. <i>Translational Oncology</i> , 2020, 13, 100791.	3.7	17
102	Immune checkpoint inhibitors alone vs immune checkpoint inhibitorsâ€”combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis. <i>British Journal of Cancer</i> , 2022, 127, 948-956.	6.4	17
103	Conventional Hypoglycaemic Agents and the Risk of Lung Cancer in Patients with Diabetes: A Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e99577.	2.5	16
104	Video-assisted thoracoscopic surgery and thoracotomy during lobectomy for clinical stage I non-small-cell lung cancer have equivalent oncological outcomes: A single-center experience of 212 consecutive resections. <i>Oncology Letters</i> , 2015, 9, 1364-1372.	1.8	16
105	Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology. <i>Cancer Biology and Medicine</i> , 2019, 16, 189.	3.0	16
106	The KIF5B-RET Fusion Gene Mutation as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2019, 20, e73-e76.	2.6	16
107	Geranylgeranyl diphosphate synthase 1 knockout ameliorates ventilator-induced lung injury via regulation of TLR2/4-AP-1 signaling. <i>Free Radical Biology and Medicine</i> , 2020, 147, 159-166.	2.9	16
108	Twist1-mediated 4E-BP1 regulation through mTOR in non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 33006-33018.	1.8	16

#	ARTICLE	IF	CITATIONS
109	Circulating soluble intercellular adhesion molecule-1 in lung cancer: a systematic review. Translational Lung Cancer Research, 2012, 1, 36-44.	2.8	16
110	Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multicenter study. Cancer Science, 2020, 111, 679-686.	3.9	15
111	A large real-world cohort study of examined lymph node standards for adequate nodal staging in early non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 815-825.	2.8	15
112	Prognostic value of wingless-type proteins in non-small cell lung cancer patients: a meta-analysis. Translational Lung Cancer Research, 2016, 5, 436-442.	2.8	15
113	Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of China. Journal of Thoracic Oncology, 2022, 17, 816-826.	1.1	15
114	Combining stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 4368-4379.	2.8	15
115	Biodegradable Porous Polymeric Drug with pH-Stimuli-Responsive Delivery Capacity for Combined Cancer Therapy. ACS Applied Polymer Materials, 2022, 4, 714-724.	4.4	15
116	The role of serum carcinoembryonic antigen in predicting responses to chemotherapy and survival in patients with non-small cell lung cancer. Journal of Cancer Research and Therapeutics, 2014, 10, 239.	0.9	14
117	Lung adenocarcinoma patient with an EGFR kinase domain duplication (KDD) and the response to icotinib. Journal of Thoracic Disease, 2018, 10, E359-E363.	1.4	14
118	Plasma mtDNA Analysis Aids in Predicting Pancreatic Necrosis in Acute Pancreatitis Patients: A Pilot Study. Digestive Diseases and Sciences, 2018, 63, 2975-2982.	2.3	14
119	Zebrafish Xenograft Model of Human Lung Cancer for Evaluating Osimertinib Resistance. BioMed Research International, 2019, 2019, 1-10.	1.9	14
120	Comparison between closed pleural biopsy and medical thoracoscopy for the diagnosis of undiagnosed exudative pleural effusions: a systematic review and meta-analysis. Translational Lung Cancer Research, 2020, 9, 446-458.	2.8	14
121	The diagnostic yield of closed needle pleural biopsy in exudative pleural effusion: a retrospective 10-year study. Annals of Translational Medicine, 2020, 8, 491-491.	1.7	14
122	Early diagnosis of solitary pulmonary nodules. Journal of Thoracic Disease, 2013, 5, 830-40.	1.4	14
123	Effect of Adjuvant Chemotherapy on Survival of Patients With 8th Edition Stage IB Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 784289.	2.8	14
124	Lipid Metabolism: Immune Regulation and Therapeutic Prospectives in Systemic Lupus Erythematosus. Frontiers in Immunology, 2022, 13, 860586.	4.8	14
125	Predictive and prognostic significance of circulating endothelial cells in advanced non-small cell lung cancer patients. Tumor Biology, 2015, 36, 9031-9037.	1.8	13
126	Adenosine Triphosphate Promotes Allergen-Induced Airway Inflammation and Th17 Cell Polarization in Neutrophilic Asthma. Journal of Immunology Research, 2017, 2017, 1-10.	2.2	13

#	ARTICLE	IF	CITATIONS
127	Protein regulator of cytokinesis-1 expression: prognostic value in lung squamous cell carcinoma patients. <i>Journal of Thoracic Disease</i> , 2017, 9, 2054-2060.	1.4	13
128	Plasma long noncoding RNA IL-6R as a prognostic biomarker for clinical outcomes in patients with acute respiratory distress syndrome. <i>Clinical Respiratory Journal</i> , 2018, 12, 1607-1614.	1.6	13
129	Irinotecan, topotecan, paclitaxel or docetaxel for second-line treatment of small cell lung cancer: a single-center retrospective study of efficiency comparison and prognosis analysis. <i>Translational Lung Cancer Research</i> , 2019, 8, 829-837.	2.8	13
130	Diagnostic Value of Mutation-Specific Antibodies for Immunohistochemical Detection of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e105940.	2.5	12
131	Prognostic value of secreted phosphoprotein-1 in pleural effusion associated with non-small cell lung cancer. <i>BMC Cancer</i> , 2014, 14, 280.	2.6	12
132	Topotecan alleviates ventilator-induced lung injury via NF- κ B pathway inhibition. <i>Cytokine</i> , 2018, 110, 381-388.	3.2	12
133	Identification of a Novel Icotinib-Sensitive EGFR-SEPTIN14 Fusion Variant in Lung Adenocarcinoma by Next-Generation Sequencing. <i>Journal of Thoracic Oncology</i> , 2019, 14, e181-e183.	1.1	12
134	A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer â€” The FALUCA study. <i>Lung Cancer</i> , 2020, 146, 252-262.	2.0	12
135	Pseudogene KRT17P3 drives cisplatin resistance of human NSCLC cells by modulating miR-497a-5p/mTOR. <i>Cancer Science</i> , 2021, 112, 275-286.	3.9	12
136	Prognostic value of lymph node ratio in patients with pathological N1 non-small cell lung cancer: a systematic review with meta-analysis. <i>Translational Lung Cancer Research</i> , 2016, 5, 258-264.	2.8	11
137	Comparison of clinical and radiological characteristics between anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation in treatment naïve advanced lung adenocarcinoma. <i>Journal of Thoracic Disease</i> , 2017, 9, 3927-3937.	1.4	11
138	A Patient With Lung Adenocarcinoma With BRAF Gene Fusion and Response to Vemurafenib. <i>Clinical Lung Cancer</i> , 2019, 20, e224-e228.	2.6	11
139	The Predictive Value of Clinical and Molecular Characteristics of Immunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Oncology</i> , 2021, 11, 732214.	2.8	11
140	The imaging of small pulmonary nodules. <i>Translational Lung Cancer Research</i> , 2017, 6, 62-67.	2.8	10
141	Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib. <i>Journal of Translational Medicine</i> , 2018, 16, 93.	4.4	10
142	Real-world efficacy and potential mechanism of resistance of icotinib in Asian advanced non-small cell lung cancer with EGFR uncommon mutations: A multi-center study. <i>Cancer Medicine</i> , 2020, 9, 12-18.	2.8	10
143	CD39+ Regulatory T Cells Attenuate Lipopolysaccharide-Induced Acute Lung Injury via Autophagy and the ERK/FOS Pathway. <i>Frontiers in Immunology</i> , 2020, 11, 602605.	4.8	10
144	Serum Exosomal miRNA Might Be a Novel Liquid Biopsy to Identify Leptomeningeal Metastasis in Non-Small Cell Lung Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2327-2335.	2.0	10

#	ARTICLE	IF	CITATIONS
145	Lesion with morphologic feature of organizing pneumonia (OP) in CT-guided lung biopsy samples for diagnosis of bronchiolitis obliterans organizing pneumonia (BOOP): a retrospective study of 134 cases in a single center. <i>Journal of Thoracic Disease</i> , 2014, 6, 1251-60.	1.4	10
146	Transthoracic needle aspiration in solitary pulmonary nodule. <i>Translational Lung Cancer Research</i> , 2017, 6, 76-85.	2.8	9
147	Evaluation of the Lung Immune Prognostic Index in Non-Small Cell Lung Cancer Patients Treated With Systemic Therapy: A Retrospective Study and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 670230.	2.8	9
148	A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non-Small Cell Lung Cancer: a Multicenter Phase I/II Study. <i>Clinical Cancer Research</i> , 2022, 28, 1127-1135.	7.0	9
149	AS-tDR-007872: A Novel tRNA-Derived Small RNA Acts an Important Role in Non-Small-Cell Lung Cancer. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-11.	1.3	9
150	Clinical outcomes of CyberKnife stereotactic radiosurgery for elderly patients with presumed primary stage I lung cancer. <i>Translational Lung Cancer Research</i> , 2017, 6, 6-13.	2.8	8
151	Eosinophil peroxidase over-expression predicts the clinical outcome of patients with primary lung adenocarcinoma. <i>Journal of Cancer</i> , 2019, 10, 1032-1038.	2.5	8
152	Efficacy of rapid on-site evaluation for diagnosing pulmonary lesions and mediastinal lymph nodes: a systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2019, 8, 1029-1044.	2.8	8
153	Association of the metformin with the risk of lung cancer: a meta-analysis. <i>Translational Lung Cancer Research</i> , 2013, 2, 259-63.	2.8	8
154	A Multicenter Retrospective Study on the Prognosis of Stage III Unresectable Mutant Non-Small Cell Lung Cancer With Tyrosine Kinase Inhibitors Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 692703.	2.8	7
155	A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. <i>Translational Lung Cancer Research</i> , 2018, 7, 428-436.	2.8	7
156	Diagnostic and prognostic significance of lysophosphatidic acid in malignant pleural effusions. <i>Journal of Thoracic Disease</i> , 2014, 6, 483-90.	1.4	7
157	Response to first-line chemotherapy of docetaxel combined with platinum predicting the prognosis and subsequent treatment of patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2014, 5, 337-342.	1.9	6
158	Chloroquine inhibits tumor growth and angiogenesis in malignant pleural effusion. <i>Tumor Biology</i> , 2016, 37, 16249-16258.	1.8	6
159	Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status. <i>Scientific Reports</i> , 2017, 7, 8483.	3.3	6
160	Rhubarb vs. glycerin enema for treatment of critically ill patients with intra-abdominal hypertension. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 855-861.	1.8	6
161	A novel co-existing <i>ZCCHC8-ROS1</i> and de-novo <i>MET</i> amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib. <i>Cancer Biology and Therapy</i> , 2018, 19, 1097-1101.	3.4	6
162	Combination of apatinib and docetaxel in treating advanced non-squamous non-small cell lung cancer patients with wild-type EGFR: a multi-center, phase II trial. <i>Journal of Thoracic Disease</i> , 2020, 12, 2450-2458.	1.4	6

#	ARTICLE	IF	CITATIONS
163	Novel risk scoring system for immune checkpoint inhibitors treatment in non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 776-789.	2.8	6
164	Antibiotic exposure windows and the efficacy of immune checkpoint blockers in patients with cancer: a meta-analysis. Annals of Palliative Medicine, 2021, 10, 2709-2722.	1.2	6
165	Association of MUC19 Mutation With Clinical Benefits of Anti-PD-1 Inhibitors in Non-small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 596542.	2.8	6
166	International consensus on severe lung cancer—the first edition. Translational Lung Cancer Research, 2021, 10, 2633-2666.	2.8	6
167	Serum neurofilament light chain or glial fibrillary acidic protein in the diagnosis and prognosis of brain metastases. Journal of Neurology, 2022, 269, 815-823.	3.6	6
168	A narrative review of progress in diagnosis and treatment of small cell lung cancer patients with hyponatremia. Translational Lung Cancer Research, 2020, 9, 2469-2478.	2.8	6
169	F-circEA1 regulates cell proliferation and apoptosis through ALK downstream signaling pathway in non-small cell lung cancer. Human Cell, 2022, 35, 260-270.	2.7	6
170	Pollutional haze as a potential cause of lung cancer. Journal of Thoracic Disease, 2015, 7, E412-7.	1.4	6
171	MDT is still important in the treatment of early stage lung cancer. Journal of Thoracic Disease, 2018, 10, S3984-S3985.	1.4	5
172	The prognostic value of longitudinal circulating tumor DNA profiling during osimertinib treatment. Translational Lung Cancer Research, 2021, 10, 326-339.	2.8	5
173	Geranylgeranyl diphosphate synthase deficiency hyperactivates macrophages and aggravates lipopolysaccharide-induced acute lung injury. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 320, L1011-L1024.	2.9	5
174	A narrative review of advances in treatment and survival prognosis of HER2-positive malignant lung cancers. Journal of Thoracic Disease, 2021, 13, 3708-3720.	1.4	5
175	Neoadjuvant Programmed Cell Death Protein-1 Blockade Combined With Stereotactic Body Radiation Therapy for Stage III(N2) Non-Small Cell Lung Cancer: A Case Series. Frontiers in Oncology, 2022, 12, 779251.	2.8	5
176	A standard for hilar and intrapulmonary lymph node dissection and pathological examination in early non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 4587-4599.	2.8	5
177	Recurrent "pneumonia" in left lower lobe lasting for 8 years: a case report. Translational Lung Cancer Research, 2016, 5, 356-362.	2.8	4
178	Three new disease-progression modes in NSCLC patients after EGFR-TKI treatment by next-generation sequencing analysis. Lung Cancer, 2018, 125, 43-50.	2.0	4
179	¹⁸ F-fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis of benign pulmonary lesions in sarcoidosis. Translational Lung Cancer Research, 2019, 8, 208-213.	2.8	4
180	Geranylgeranyl diphosphate synthase deficiency aggravates lung fibrosis in mice by modulating TGF- β 1/BMP-4 signaling. Biological Chemistry, 2019, 400, 1617-1627.	2.5	4

#	ARTICLE	IF	CITATIONS
181	Neutrophil-derived long noncoding RNA IL-7R predicts development of multiple organ dysfunction syndrome in patients with trauma. <i>European Journal of Trauma and Emergency Surgery</i> , 2020, , 1.	1.7	4
182	Contrast-enhanced computed tomography prior to percutaneous transthoracic needle biopsy reduces the incidence of hemorrhage. <i>Annals of Translational Medicine</i> , 2021, 9, 288-288.	1.7	4
183	Predictive and prognostic values of circulating tumor DNA (ctDNA) clearance in osimertinib treated advanced non-small cell lung cancer cohort.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3036-3036.	1.6	4
184	Detection of oncogenic mutations in resected bronchial margins by next-generation sequencing indicates early relapse in stage IA lung adenocarcinoma patients. <i>Oncotarget</i> , 2017, 8, 40643-40653.	1.8	4
185	Erlotinib-based doublet targeted therapy versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis from 24 randomized controlled trials. <i>Oncotarget</i> , 2017, 8, 73258-73270.	1.8	4
186	Overexpression of Raf-1 kinase inhibitor protein inhibits cell invasion and migration in lung cancer cells through suppressing epithelial-mesenchymal transition. <i>Translational Cancer Research</i> , 2019, 8, 2295-2306.	1.0	4
187	CHRNA3 rs1051730 polymorphism and lung cancer susceptibility in Asian population: a meta-analysis. <i>Translational Lung Cancer Research</i> , 2015, 4, 104-8.	2.8	4
188	Intrapleural Injection of Anti-PD1 Antibody: A Novel Management of Malignant Pleural Effusion. <i>Frontiers in Immunology</i> , 2021, 12, 760683.	4.8	4
189	Assessing the clinical outcome of nab-paclitaxel in Chinese patients with advanced non-small cell lung cancer. <i>Clinical Respiratory Journal</i> , 2017, 11, 632-639.	1.6	3
190	A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel. <i>ESMO Open</i> , 2017, 2, e000174.	4.5	3
191	Intracavitary chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is not superior to TKI monotherapy in controlling malignant pleural effusion recurrence in EGFR-mutated lung cancer patients. <i>Journal of Thoracic Disease</i> , 2019, 11, 3712-3720.	1.4	3
192	Case Report: A Rare Case of Metachronous Multiple Primary Lung Cancers in a Patient With Successful Management by Switching From Anti-PD-1 Therapy to Anti-PD-L1 Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 683202.	4.8	3
193	Lung adenocarcinoma patient with EGFR 19 exon insert mutation and its response to icotinib. <i>Lung Cancer</i> , 2018, 121, 101-104.	2.0	2
194	The correlation between crizotinib efficacy and molecular heterogeneity by next-generation sequencing in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 2948-2959.	1.4	2
195	Development of RECLS score to predict survival in lung cancer patients with malignant pleural effusion. <i>Translational Lung Cancer Research</i> , 2021, 10, 1318-1326.	2.8	2
196	The expression landscape of JAK1 and its potential as a biomarker for prognosis and immune infiltrates in NSCLC. <i>BMC Bioinformatics</i> , 2021, 22, 471.	2.6	2
197	Preface on "pulmonary nodules special issue for lung cancer". <i>Translational Lung Cancer Research</i> , 2017, 6, 1-2.	2.8	2
198	Multicenter study of diagnostic procedures, genetic aberration analysis, and first-line treatment of lung cancer in Jiangsu Province, China. <i>Thoracic Cancer</i> , 2018, 9, 376-383.	1.9	1

#	ARTICLE	IF	CITATIONS
199	Diagnosis status and pathological diagnosis derived treatment of elderly lung cancer patients over 75 years old. Translational Cancer Research, 2019, 8, 87-95.	1.0	1
200	Could cell division cycle protein 42 be a target for lung cancer treatment?. Translational Cancer Research, 2019, 8, 312-318.	1.0	1
201	comparison to DP in the first-line treatment of phase IIIb/IV squamous-cell NSCLC (JSLCG-001): A multicenter, open-label, randomized phase III controlled study (NCT: 02513342).. Journal of Clinical Oncology, 2019, 37, e20541-e20541.	1.6	1
202	Carcinoembryonic antigen in pleural effusion of patients with lung adenocarcinoma: a predictive marker for EGFR mutation. Translational Cancer Research, 2019, 8, 1027-1034.	1.0	1
203	Simultaneous in situ detection of protein expression of multiple tumor markers of circulating tumor cells and heteroploid of chromosome 8 in primary lung cancer. Annals of Translational Medicine, 2021, 9, 1772-1772.	1.7	1
204	How to diagnose pulmonary nodules: from screening to therapy. Translational Lung Cancer Research, 2017, 6, 3-5.	2.8	0
205	The pulmonary nodule “discovered” by pneumonia: a case report. Translational Lung Cancer Research, 2017, 6, 92-96.	2.8	0
206	Neutrophil to lymphocyte ratio as a prognostic indicator for advanced non-small cell lung cancer patients: A retrospective study.. Journal of Clinical Oncology, 2012, 30, e18082-e18082.	1.6	0
207	Gefitinib as third-line re-challenge treatment in advanced NSCLC patients with <i>EGFR</i> activating mutation who benefited from first-line gefitinib treatment followed by second-line chemotherapy.. Journal of Clinical Oncology, 2017, 35, 9035-9035.	1.6	0
208	Multiple intercostal neurilemmomas in a Chinese woman. Journal of Cancer Research and Therapeutics, 2018, 14, 1220.	0.9	0
209	A pilot trial assessing apatinib combined with docetaxel (DTX) as second-line chemotherapy for EGFR negative advanced non-small-cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2018, 36, e21113-e21113.	1.6	0
210	Efficacy and safety of IBI305 compared with bevacizumab in advanced non-squamous NSCLC patients as first-line treatment in a randomized, double-blind, phase III study.. Journal of Clinical Oncology, 2019, 37, 9095-9095.	1.6	0
211	Status quo and prospects of the translational research on lung cancer in China. Translational Lung Cancer Research, 2012, 1, 91-3.	2.8	0
212	Induction of type II alveolar epithelial cells apoptosis in mouse by lipopolysaccharide does not require TNF-alpha. Chinese Medical Journal, 2003, 116, 625-9.	2.3	0